Clinical Trial Update: A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the long-term safety of a fixed-dose combination of lifitegrast and perfluorohexyloctane for dry eye disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Lifitegrast (lifitegrast)
• Perfluorohexyloctane (perfluorohexyloctane)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Dry Eye Disease | Phase 3 | Status: WITHDRAWN